Central Asia Metals Plc (CAML)
London Exchange · UK · prices in GBX · close of 22 Oct 2026
Key indicators
| Last close | GBX 133.40 |
|---|---|
| 52-week range | 125.27 – 244.00 |
| Return, 1 month / 3 months | −17.8% / −4.8% |
| Return, 1 year / 3 years | −2.7% / +11.9% |
| Trend | Below its 200-day average |
| RSI (14) | 27 |
| Volatility (1 year) | 43.4% |
| Worst drawdown (1 year) | -44.5% |
| Average daily value traded | 190.74M GBX |
| Dividend yield | 11.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Central Asia Metals is a mining company based in London that produces copper and zinc-lead concentrates. Its main operation in Kazakhstan recovers copper from old waste dumps at the Kounrad site, turning material left by earlier mining into copper cathode. The company also runs the Sasa underground mine in North Macedonia, which yields zinc and lead concentrates. Its customers are industrial metal buyers and smelters that process these raw materials for manufacturing and construction uses.
On this site Central Asia Metals Plc appears as a stock on the London Exchange (UK), code CAML, with prices in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Central Asia Metals Plc (CAML) trades on the London Exchange in UK. It last closed at GBX 133.40 on 22 October 2026.
Its price-based Market X-Ray is 48 out of 100 (a weak price profile), ranking 2,154 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 2.7% and over the last three months it fell 4.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 29 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -13.0% | ||
| From 52-week high | -44.8% | ||
| Momentum | 51 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -4.8% | ||
| 6-month return | -1.3% | ||
| 12-month return, skipping the last month | 18.4% | ||
| Stability (higher is calmer) | 31 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 43.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -44.5% | ||
| Liquidity | 92 · Strong | Trades actively. | |
| Average daily value traded | 190.74M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | 69 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 11.6% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −8.4% |
|---|---|
| 1 month | −17.8% |
| 3 months | −4.8% |
| 6 months | −1.3% |
| 1 year | −2.7% |
| 3 years | +11.9% |
| 5 years | −13.1% |
Signals
| 50-day / 200-day average | 154.73 / 153.34 |
|---|---|
| Golden / death cross (60 days) | Golden, 8 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 6.69 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 24 Sep 2026 | GBP 0.0800 |
| 4 Jun 2026 | GBP 0.0750 |
| 25 Sep 2025 | GBP 0.0450 |
| 24 Apr 2025 | GBP 0.0900 |
| 26 Sep 2024 | GBP 0.0900 |
| 25 Apr 2024 | GBP 0.0900 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.